The results of the 2012 election have the potential to change the outlook for the pharmaceutical industry over the next four years. Philip Bonforte of FaegreBD Consulting explained possibilities the pharmaceutical industry should prepare for in the article "Fiscal Cliffhanger: The Impact of the 2012 Election on the Pharmaceutical Industry" in the November 30, 2012, issue of Bloomberg BNA's Pharmaceutical Law & Industry Report.

In the article, Bonforte describes and analyzes issues such as leadership changes on key congressional committees, the release of regulations and guidance for implementation of health care reform, changes to prescription drug taxes and Medicare reimbursement, and the potential for new regulations on the industry.